Skip to main content
. Author manuscript; available in PMC: 2017 Aug 7.
Published in final edited form as: Sci Transl Med. 2014 Jan 1;6(217):217ra2. doi: 10.1126/scitranslmed.3007048

Figure 5. siHoxA1 reduces mammary tumor cell proliferation in vivo through modulation of p44/42 MAPK signaling.

Figure 5

(A) Microarray analysis of MAPK pathway signature genes in untreated transgenic C3(1)-SV40TAg mammary glands (n = 3) at progressive disease stages. (B) The effect of bi-weekly siHoxA1 injections on protein expression of MAPK components, ERK1/2, SRC, IER3, KRAS, PCNA and GRB2, in mammary glands of 21-week old transgenic animals (n = 3) compared with injection of non-targeting control siRNA (siNT) (n = 3).